Binding assays have long been used to determine compound affinity and selectivity for various seven-transmembrane receptors. Over time, the degree of complexity has significantly reduced, whereas the throughput of the various assays has greatly increased. In this article, we detail the development of a filter-binding assay and a scintillation-proximity assay (SPA) designed to quantify a compound's affinity for the three alpha(1)-adrenoceptor subtypes, alpha(1A), alpha(1B), and alpha(1D). The various components of the assays such as ease of assay performance, robustness, cost, and generation of radioactive waste are compared and contrasted. On the basis of the results, the SPA offers many advantages of high-throughput assay formats over the traditional filter-binding assay. To follow up on the success of the alpha(1)-adrenoceptor SPA, SPAs for the three alpha(2)-adrenoceptors were developed and are detailed in this article. Affinity data generated for a select number of oz compounds agree with reported literature values. These assays, like those for a, subtypes, are very amenable to high-throughput screening campaigns. In conclusion, scintillation-proximity assays offer significant advantages over filter-binding assays. (C) 2000 Elsevier Science Inc. All rights reserved.
